Investors Allege Caribou Oversold Cancer Therapy's Promise
Shareholders hit Caribou Biosciences Inc. with a class action Tuesday alleging the gene-editing biotechnology firm misled investors about the durability of its top cancer-fighting therapy leading up to and after its...To view the full article, register now.
Already a subscriber? Click here to view full article